Pravin Chaturvedi

Pravin R. Chaturvedi is a prominent figure in the pharmaceutical and biotechnology industries, currently serving as the President and Chief Executive Officer of Pivot Pharmaceuticals, a position he has held since 2015. Under his leadership, Pivot Pharmaceuticals focuses on developing and commercializing therapeutic pharmaceuticals and nutraceuticals, particularly in the areas of rare pediatric gastrointestinal diseases, pancreatic cancer, and ovarian cancer.13

Education and Early Career

Dr. Chaturvedi earned his Bachelor of Pharmacy from the University of Mumbai in 1983 and later obtained a PhD in Pharmaceutical Sciences from West Virginia University in 1988. His career began at Parke-Davis/Warner-Lambert (now part of Pfizer), where he worked in product development from 1988 to 1993. He then held various roles at Alkermes and Vertex Pharmaceuticals, where he was involved in drug development for serious diseases.123

Entrepreneurial Ventures

In addition to his role at Pivot Pharmaceuticals, Chaturvedi is a co-founder and the interim Chief Executive Officer of Oceanyx Pharmaceuticals, focusing on drug discovery based on marine cyanobacteria. He has also served as the Chief Scientific Officer at Napo Pharmaceuticals and has played significant roles in other biotech companies, including IndUS Pharmaceuticals, which merged with Pivot Pharmaceuticals during his tenure.123

Contributions to the Industry

Dr. Chaturvedi has over 30 years of experience in drug development across various therapeutic areas, including central nervous system disorders, HIV, hepatitis C, and gastrointestinal conditions. He has been instrumental in the successful commercialization of several drugs and is known for his leadership in fostering strategic partnerships within the pharmaceutical sector.13 He also serves on multiple boards and advisory panels, contributing to advancements in healthcare through collaboration and innovation.23

Personal Philosophy

Chaturvedi emphasizes the importance of making a positive impact through medicine rather than merely pursuing profit. His dedication to patient care drives his work in drug development, where he aims to address unmet medical needs effectively.13